Free Trial

BioCryst Pharmaceuticals Q3 2023 Earnings Report

BioCryst Pharmaceuticals logo
$9.21 -0.18 (-1.92%)
As of 02/21/2025 04:00 PM Eastern

BioCryst Pharmaceuticals EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

BioCryst Pharmaceuticals Revenue Results

Actual Revenue
$86.74 million
Expected Revenue
$86.54 million
Beat/Miss
Beat by +$200.00 thousand
YoY Revenue Growth
N/A

BioCryst Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A

BCRX Upcoming Earnings

BioCryst Pharmaceuticals will be holding an earnings conference call on Monday, February 24 at 8:30 AM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

Conference Call Audio

Slide Deck

BioCryst Pharmaceuticals Earnings Headlines

BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Monday
“Amazon Coin” set to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
BioCryst to Present at Upcoming Investor Conferences
See More BioCryst Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioCryst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCryst Pharmaceuticals and other key companies, straight to your email.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

View BioCryst Pharmaceuticals Profile

More Earnings Resources from MarketBeat